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Edited by Pascale CossartAbstract Ipaf has been associated with apoptosis, cytokine
processing, and nuclear factor-B activation. Here, we describe
that Ipaf is highly expressed in myelomonocytic cells and that
the mRNA levels of Ipaf progressively increase during diﬀeren-
tiation of CD34þ progenitors to granulocytes and monocytes.
Additionally, treatment with tumor necrosis factor-a and expo-
sure to UV radiation induced the transcriptional activation of
Ipaf in human leukemia HL-60 cells. Thus, Ipaf may contribute
to modulate the response of myeloid cells to genotoxic and pro-
inﬂammatory stimuli.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ipaf, also called CARD12 or CLAN, belongs to a family of
proteins structurally characterized by a nucleotide-binding
oligomerization domain (NOD) followed by multiple leucine-
rich repeats (LRRs). In addition, Ipaf contains an N-terminal
caspase recruitment domain (CARD) as already described for
other members of the family such as Nod1, Nod2 and CIITA
[1,2]. Recently, Nod proteins have been shown to recognize
bacterial components including lipopolysaccharides (LPS) and/
or bacterial muramyl dipeptide [3,4], and this interaction leads
to the activation of nuclear factor jB (NFjB), a transcription
factor that plays a central role in innate immunity and cell
survival. Very little is known about the transcriptional regula-
tion of the NOD family of proteins. Recently, it has been de-
scribed that Nod2 expression is enhanced by pro-inﬂammatory
cytokines and bacterial components via NFjB, a mechanism
that may contribute to the ampliﬁcation of the innate immune
response [5]. Furthermore, much remains to be discovered to
better elucidate the expression and function of these genes
within the hematopoietic compartment. Ipaf is highly expressed
in the bone marrow and among circulating blood leukocytes
the highest mRNA levels have been found in monocytes [6]. It
has been suggested that this CARD-containing protein may
contribute to a number of intracellular processes, including
apoptosis, cytokine processing, and NFjB activation [1,6,7].* Corresponding author. Fax: +34-942-200952.
E-mail address: ﬂuna@humv.es (J.L. Fernandez-Luna).
Abbreviations: TNFa, tumor necrosis factor-a; JNK, c-Jun N-terminal
kinase; NFjB, nuclear factor jB; EMSA, Electrophoretic mobility
shift assay; RACE, rapid ampliﬁcation of cDNA ends
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doi:10.1016/j.febslet.2004.04.095In an attempt to improve our understanding of the regula-
tion of Ipaf in hematopoietic cells, we investigated its expres-
sion in response to diﬀerent stimuli in primary cells and cell
lines. We show that Ipaf expression is increased during dif-
ferentiation of CD34þ progenitors to granulocytes and
monocytes, and that DNA damage and treatment with tumor
necrosis factor-a (TNFa) induce transactivation of Ipaf in
human leukemia HL-60 cells.2. Materials and methods
2.1. Cells
Mobilized peripheral blood progenitors and peripheral blood sub-
populations were isolated as previously described [5]. Puriﬁed CD34þ
cells (more than 95%) were seeded into 24-well culture plates at 5 104
cells/mL in Iscove’s modiﬁed Dulbecco’s medium (Invitrogen, Carls-
bad, CA), containing 20% fetal calf serum (FCS) and recombinant
human stem cell factor (SCF), interleukin-3 (IL-3) and interleukin-6
(IL-6) (Immunex, Seattle, WA) at a ﬁnal concentration of 100 ng/ml.
Granulocyte (Gr) and monocyte/macrophage (Mo) cell populations
were generated as described [5].
Human leukemia cell lines Jurkat, HL-60, K562, U937, THP-1 and
TF1 and the breast cancer cell lines MCF7 and SUM159 were main-
tained as described elsewhere [5,8]. HEK293T cells were cultured in
RPMI with 10% FCS. When indicated, HL-60 cells were treated with
lipopolysaccharide (LPS), TNFa (both from Sigma, St Louis, MO) or
irradiated with UV rays.2.2. RT-PCR and rapid ampliﬁcation of cDNA ends (RACE) analysis
Total RNA was prepared using TRIZOL reagent (Invitrogen). To
quantitate mRNA expression, a quantitative real-time PCR method
was used as previously described [5]. The generated cDNA was am-








and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [9]. The
ratio of the abundance of Ipaf transcripts to that of gapdh transcripts
was calculated as 2n, where n is the CT (threshold cycle) value of gapdh
minus the CT value of Ipaf, and normalized by the value of the sample
with the lowest expression level of Ipaf. Speciﬁcity of the desired PCR
products was determined with melting curve analysis.
Semiquantitative RT-PCR was used as previously described [5].
After 20 (GAPDH) or 32 (Ipaf) ampliﬁcation cycles, the expected PCR
products were size fractionated onto an agarose gel and stained with
ethidium bromide.
For analysis of sequences at the 50 end of Ipaf mRNA, a 50-RACE
kit was used according to the manufacturer’s instructions (Roche,
Mannheim, Germany), with the following Ipaf primers: 5TGTTC-
TGGATGAAAGCTTCCCACC3 and 5CTCTTCATTCTGGCTGA-
GCAATCC3.2.3. c-Jun N-terminal kinase (JNK) immunoassay
JNK activity was detected by an immunocomplex assay as described
elsewhere [10] with slight modiﬁcations. In brief, cell lysates wereblished by Elsevier B.V. All rights reserved.
Fig. 1. Analysis of Ipaf mRNA in primary hematopoietic cells. Total
RNA was puriﬁed from (A) CD34þ cells cultured in the presence of M-
CSF or G-CSF to induce Mo or Gr diﬀerentiation, respectively, and
(B) immune-puriﬁed peripheral blood cell populations, and subjected
to quantitative real-time PCR. Histograms represent the meansS.D.
of triplicate analyses.
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were incubated with anti-JNK1 (sc-474) (Santa Cruz Biotechnology,
Santa Cruz, CA) for 2 h at 4 C and then incubated with Gammabind
Sepharose beads (Amersham Biosciences, Piscataway, NJ). The
immune complexes were washed and resuspended in kinase buﬀer
containing [c-32P]ATP (3000 Ci/mmol; Amersham) and 1 lg of GST-
ATF2 (SIGMA). After incubation, samples were resolved by SDS–
polyacrylamide gel electrophoresis (PAGE) and autoradiography. To
ensure an even immunoprecipitation, part of the immune complexes
were run on a 10% SDS–PAGE, transferred to nitrocellulose ﬁlters and
developed with anti-JNK antibody.
2.4. Electrophoretic mobility shift assays (EMSAs)
HL-60 cells were lysed and nuclear fractions were resuspended in 20
mMHEPES, pH 7.9, 420 mMNaCl, 1 mM EDTA, 1 mM EGTA, and
20% glycerol. Nuclear extracts (5 lg of total protein) were incubated
with a 32p-labeled double stranded DNA probe containing a consensus
sequence for AP1 (TGAGTCA). Samples were run on a 5% non-de-
naturing polyacrylamide gel in 200 mM Tris-borate and 2 mM EDTA.
Gels were dried and visualized by autoradiography. Supershifts were
performed using antibodies speciﬁc for c-Jun, c-Fos or irrelevant
GATA-1 (Santa Cruz Biotechnology, Santa Cruz, CA).
2.5. Gene reporter assays
A genomic PCR fragment of 788 bp from the promoter region of
Ipaf (Ipafpt) (nucleotide positions 89533 to 90320 from GenBank
Accession No. AL121653) was cloned into XhoI and HindIII sites of
the pGL2-basic luciferase reporter vector (Promega Corp., Madison,
WI). The authenticity of the construct was conﬁrmed by sequencing.
HEK293T cells were cotransfected with 1 lg of pGL2-Ipafpt and 50 ng
of pRSV-b-gal in triplicate by using FuGENE 6 reagent (Roche).
Twenty four hours post-transfection, cells were treated with 30 ng/mL
of TNFa or brieﬂy exposed to UV light (400 J/m2) and then left in
culture. After 12 h of incubation, cell extracts were prepared and an-
alyzed for the relative luciferase activity by a dual-light reporter gene
assay system (Applied Biosystems, Foster City, CA). Results were
normalized for transfection eﬃciency with values obtained with
pRSV-b-gal.Fig. 2. Analysis of Ipaf mRNA in hematopoietic and epithelial cell
lines. RNA was obtained from myelomonocytic (HL-60, TF1, U937,
THP-1, K562), lymphoblastic (Jurkat) and breast cancer epithelial
(MCF7, SUM159) cell lines, and subjected to quantitative real-time
PCR. Histograms represent the means S.D. of triplicate analyses.3. Results and discussion
We have focussed on the expression pattern of Ipaf and the
identiﬁcation of its inducers in a wide range of hematopoietic
populations. First, we puriﬁed CD34þ progenitors from pe-
ripheral blood, and the selected population was cultured with
colony stimulating factors (CSF) for either granulocytes (G-
CSF) or monocytes (M-CSF) for diﬀerent time intervals to
induce Gr or Mo maturation, as previously described [5].
CD34þ progenitor cells expressed low levels of Ipaf (Fig. 1A,
and data not shown), which increased about 5-fold by day 10
and 10–15-fold by day 20 of culture in both monocytic and
granulocytic lineages (Fig. 1A). Thus, Ipaf is upregulated
along the myelomonocytic diﬀerentiation. Then, we analyzed
the expression of Ipaf in peripheral blood populations of B
cells (CD19þ), T cells (CD3þ), granulocytes (CD15þ), mono-
cytes (CD14þ), and monocyte-derived dendritic cells (CD40þ/
CD86þ). Real-time PCR analysis showed that B lymphocytes
expressed very low levels of Ipaf, whereas the other cell pop-
ulations expressed 60–100-fold more Ipaf mRNA than B cells,
with the highest levels detected in granulocytes and monocytes
(Fig. 1B). A similar expression pattern has been described for
Nod2, another member of the NOD family of proteins [5].
Thus, both Ipaf and Nod2 are preferentially expressed in pri-
mary myelomonocytic cells. Finally, we studied the expression
of Ipaf in a number of cell lines including myelomonocytic
(HL-60, TF1, U937, THP-1, K562), lymphoblastic (Jurkat),
and breast cancer epithelial (MCF7, SUM159) cells. As shownin Fig. 2, the highest expression levels of Ipaf were observed in
HL-60, TF1, THP-1 and U937. The expression pattern found
for Ipaf partly correlates with previous data showing that
among peripheral blood leukocytes, only monocytes expressed
Ipaf [6]. However, we have shown that granulocytes express
Fig. 4. Transcriptional activation of the Ipaf promoter. HEK293T cells
were transfected with a luciferase reporter vector containing a 788-bp
fragment from a putative promoter region of the Ipaf gene, in the
presence of pRSV-b-gal. Cells were left untreated (C), or induced with
TNFa or UV light for 12 h. Arbitrary units (a.u.) of luciferase activity
were normalized based on values of pRSV-b-gal activity to control for
transfection eﬃciency. Data are presented as the mean of triplicate
culturesS.D.
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explanation for this diﬀerence is that we have used highly
puriﬁed primary cell subpopulations instead of leukocytes
separated by centrifugation and adherence to plastic dishes,
which reduces the possibilities of cell contamination that may
hinder the gene expression data when using ampliﬁcation
techniques such as real-time or semiquantitative PCR.
As Ipaf has been associated with activation of downstream
apoptotic and inﬂammatory signaling pathways, we estimu-
lated human leukemia HL-60 cells with TNFa, a major me-
diator of apoptosis as well as inﬂammation. After 24 h of
treatment with TNFa, the mRNA levels of Ipaf increased
about 8-fold (Fig. 3A). TNFa triggers the activation of two
major transcription factors: NFjB and c-Jun [11]. However,
treatment with bacterial LPS, a well known activator of the
NFjB pathway, failed to modify the expression of Ipaf
(Fig. 3A), which leaves c-Jun as a likely candidate for the
transcriptional regulation of Ipaf. This was further conﬁrmed
by exposure of cells to UV radiation, a genotoxic stimulus that
activates JNK, which in turn activates c-Jun [12]. Both TNFa
and UV exposure induced the phosphorylation activity of JNK
as assessed by an immune complex kinase assay (Fig. 3B), and
increased the DNA binding activity of AP1 heterodimer con-
taining c-Jun and c-Fos as determined by EMSA (Fig. 3C).Fig. 3. Induction of Ipaf mRNA in response to UV and TNFa. (A)
HL-60 cells were treated with 10 lg/mL LPS or 10 ng/mL TNFa for 24
h, or brieﬂy exposed to UV radiation (400 J/m2) and left in culture for
24 h. Then, total RNA was isolated and analyzed for the expression of
Ipaf by real-time PCR. Histograms represent the meansS.D. of
triplicate analyses. (B) Cells were treated as in A but the incubation
time was shortened to 30 min. After incubation, cells were subjected to
an immune complex JNK assay with GST-ATF2 as substrate. (C)
Cells were treated with 30 ng/mL TNFa for 3 h or exposed to UV (400
J/m2) and left in culture for 1 h, and the formation of AP1–DNA
complexes was determined by an EMSA using radiolabeled consensus
probe. Nuclear extracts were preincubated with 100-fold molar excess
of unlabeled AP1 probe (100 SP), unlabeled irrelevant probe (100
NSP), or with antibodies against c-Jun, c-Fos or GATA1.Consistently, the mRNA levels of Ipaf increased more than 4-
fold in reponse to UV radiation (Fig. 3A).
In order to validate these data, we attempted to study the
Ipaf promoter region. However, diﬀerent transcription start
sites are found within a genomic sequence of about 1 kb as
assessed by 50-RACE [6] (data not shown). Furthermore, we
cannot rule out the presence of other transcripts with shorter 50
ends, as non-characterized smaller PCR products were ob-
tained in the 50-RACE analysis. This would be consistent with
the big 50 untranslated tale of more than 9 kb formed by three
diﬀerent exons as deduced from the genomic sequence of Ipaf.
With the caveat that we may be missing critical regulatory
sequences, a genomic fragment of 788 bp spanning a region
overlapping the most 50 transcription start site was cloned into
a promoterless luciferase vector, and this construct was tran-
siently transfected into HEK293T cells. As shown in Fig. 4,
treatment with TNFa or UV exposure induced the transcrip-
tional activity between 8- and 14-fold when compared with
unstimulated cells. A search for transcriptional factor binding
sites with MatInspector software (Genomatix, Munich, Ger-
many) identiﬁed a number of putative consensus sites for
transcriptional activators (CREB, Stat, E2F, forkhead-related
activators) and repressors (Gﬁ1, E4BP4). Although in the ge-
nomic fragment analyzed there are no perfect matches to the
AP1 core sequence, at least one AP1-like binding site
(TGACACT) was identiﬁed. Thus, we suggest that an AP1
consensus sequence located in either this or other genomic
region is a likely candidate to contribute to Ipaf expression due
to the clear correlation found between AP1 activation and
increase in the mRNA levels of Ipaf. Alternatively, other
transcription factors may be involved. Consistent with this
second hypothesis, CREB, Stat and E2F are activated by UV
radiation and/or treatment with TNFa [13–16].
In conclusion, our study shows that Ipaf is upregulated
during diﬀerentiation of CD34þ progenitors along the granu-
locyte and monocyte lineages. Our data also suggest that ge-
notoxic or pro-inﬂammatory stimuli induce the expression of
Ipaf at the transcriptional level in leukemia cells.
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